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Resource table

  --------------------------------------- -------------------------------------------------------------------------------------------------------------------------------
  Unique stem cell line identifier        TRNDi006-A

  Alternative name(s) of stem cell line   HT527A

  Institution                             National Institutes of Health\
                                          National Center for Advancing Translational Sciences\
                                          Bethesda, Maryland, USA

  Contact information of distributor      Dr. Wei Zheng\
                                          <Wei.Zheng@nih.gov>

  Type of cell line                       iPSC

  Origin                                  Human

  Additional origin info                  Age: 1-year-old\
                                          Sex: Female\
                                          Ethnicity: Caucasian

  Cell Source                             Dermal fibroblasts

  Clonality                               Clonal

  Method of reprogramming                 Integration-free Sendai viral vectors

  Genetic Modification                    NO

  Type of Modification                    N/A

  Associated disease                      Mucopolysaccharidosis type III B (MPS IIIB)

  Gene/locus                              *NAGLU*^Glu153Lys^

  Method of modification                  N/A

  Name of transgene or resistance         N/A

  Inducible/constitutive system           N/A

  Date archived/stock date                2018

  Cell line repository/bank               N/A

  Ethical approval                        NIGMS Informed Consent Form was obtained from patient at time of sample submission. Confidentiality Certificate: CC-GM-15-004
  --------------------------------------- -------------------------------------------------------------------------------------------------------------------------------

Resource utility {#S1}
================

This TRNDi006-A iPSC line is a valuable resource for elucidating the disease phenotype and pathophysiology of MPS IIIB. It can be differentiated into various mature cell types for use as cell-based disease models of MPS IIIB for compound screening and drug development.

Resource details {#S2}
================

MPS IIIB, also known as Sanfilippo syndrome type B, is an inherited lysosomal storage disease caused by mutations in the *NAGLU* gene, which encodes *N*-acetylglucosaminidase, which normally degrades heparin sulfate ([@R4]). Heparin sulfate proteoglycans can bind to many ligands to modulate various cellular activities and maintain tissue architecture and physiology. Deficiency of *N*-acet-ylglucosaminidase's function causes lysosomal accumulation of heparin sulfate resulting in neurological dysfunction in MPS IIIB patients ([@R1]), though the exact mechanism of MPS IIIB disease is unclear. Children with MPS IIIB have severe neurological and behavioral defects, leading to death in the second or third decade of life. Currently, there are no effective treatments for MPS IIIB. The clinical treatments for this disease are symptomatic and palliative that do not improve patient prognosis.

In this study, an iPSC line was established from skin fibroblasts of a 1-year-old female patient carrying a homozygous gene mutation of p.Glu153Lys (c.457 G \> A) in the *NAGLU* gene by using a non-integrating Sendai viral vector kit (A16517, ThermoFisher) containing OCT¾, KLF4, SOX2 and C-MYC pluripotency transcription factors ([@R2]; [@R3]). Mutations of the *NAGLU* gene in the newly generated iPSC line, designated as TRNDi006-A, were confirmed by Sanger sequencing of the PCR product harboring the single nucleotide variation (SNV) ([Fig. 1D](#F1){ref-type="fig"}). The patient-derived iPS cells exhibited classical embryonic stem cell morphology ([Fig. 1A](#F1){ref-type="fig"}) and a normal karyotype (46, XX) that was confirmed by G-banded karyotyping at passage 15 ([Fig 1C](#F1){ref-type="fig"}). The cells expressed the major plur- ipotent protein markers of NANOG, SOX2, OCT4, SSEA4 and TRA-1--60 ([Fig. 1](#F1){ref-type="fig"} A, B) as evidenced by both immunofluorescence staining and flow cytometry analysis. Sendai virus vector (SeV) clearance was detected with reverse transcription polymerase chain reaction (RT-PCR) using SeV-specific primers with no virus present by passage 15 ([Fig. 1E](#F1){ref-type="fig"}). Mycoplasma testing was performed for the TRNDi006-A cell line and a negative result was obtained ([Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}). The iPSC line was authenticated using STR DNA profiling analysis which demonstrated matching genotypes at all 18 loci examined (information available from the authors). Furthermore, a teratoma formation experiment demonstrated pluripotency of this iPS cell line, as it exhibited its ability to differentiate into tissues of all three germ layers (ectoderm, neural tube; mesoderm, cartilage; endoderm, gut) *in vivo* ([Fig. 1F](#F1){ref-type="fig"}). (See [Table 1](#T1){ref-type="table"}.)

Materials and methods {#S3}
=====================

Cell culture {#S4}
------------

Patient skin fibroblasts, obtained from Coriell Institute (GM01426), were cultured in DMEM supplemented with 10% fetal bovine serum, 100 units/ml penicillin and 100μg/ml streptomycin in a humidified incubator with 5% CO~2~ at 37 °C. The iPSCs were cultured in StemFlex medium (ThermoFisher) on matrigel (Corning, 354277)-coated plates at 37 °C in humidified incubator with 5% CO~2~ and 5% O~2~. Cells were passaged with the dissociation agent of 0.5 mM ethylenediaminetetraacetic acid (EDTA) at 80% confluency.

Reprogramming of human skin fibroblasts {#S5}
---------------------------------------

Non-integrating Sendai virus was used to reprogram patient-derived fibroblasts into iPS cells. Methods were described previously ([@R2]; [@R3]).

Genome analysis {#S6}
---------------

Genomic analysis of *NAGLU* variants was performed by Applied StemCell (Milpitas, California). Genomic DNA was extracted from TRNDi006-A using QuickExtract™ DNA Extraction Solution (Lucigen) and PCR amplifications using MyTaq™ Red Mix (Bioline) were carried out using a previously defined protocol ([@R5]). Sanger sequencing analysis was used for genotyping of the homozygous mutation for a p. Glu153Lys variant (c.457 G \> A) of the *NAGLU* gene. The specific primers used in these protocols are listed in [Table 2](#T2){ref-type="table"}.

Immunocytochemistry {#S7}
-------------------

The iPSCs were fixed with 4% paraformaldehyde, and permeabi- lized with 0.3% Triton X-100. Cells were treated overnight at 4 °C with SOX2, OCT4, NANOG, SSEA4 and TRA-1-60 primary antibodies ([Table 2](#T2){ref-type="table"}). After washing, cells were incubated with secondary antibodies conjugated with Alexa Fluor 488 or Alex Fluor 594. Cells were stained with Hoechst 33342 and imaged with an INCell Analyzer 2200 imaging system (GE Healthcare) using 20× objectives and Texas Red, FITC, and DAPI filter sets.

Flow cytometry analysis {#S8}
-----------------------

Cells were dissociated using TrypLE (ThermoFisher), fixed with 4% paraformaldehyde. Prior to fluorescence-activated cell sorting, cells were permeabilized with 0.2% Tween-20 in Dulbecco's Phosphate Buffered Saline (DPBS)D and stained with fluorophore-conjugated antibodies for 1 h at 4°C on a shaker. Relative fluorophore-conjugated animal nonimmune immunoglobulin were used as the negative control (Antibodies and nonimmune immunoglobulin used are listed in [Table 2](#T2){ref-type="table"}). Cells were then analyzed on Accuri™ C6 Flow Cytometry system (BD Biosciences).

G-banded karyotyping {#S9}
--------------------

The G-banding karyotype analysis was conducted at WiCell Research Institute (Madison, WI, USA). A total of 20 randomly selected metaphases were analyzed by G-banding for each cell line.

Short tandem repeat (STR) analysis {#S10}
----------------------------------

Samples for cell line authentication were analyzed by the Johns Hopkins University Genetic Resources core facility using a PowerPlex 18D Kit (Promega) and the PCR product was electrophoresed on an ABI Prism® 3730×1 Genetic Analyzer. Data were analyzed using GeneMapper® v 4.0 software (Applied Biosystems).

Mycoplasma detection {#S11}
--------------------

Mycoplasma status was assessed using the Lonza MycoAlert kit following the manufacturer protocol. A ratio of B/A \< 0.9 indicates a mycoplasma negative sample.

Sendai virus detection {#S12}
----------------------

For positive controls, human fibroblasts (Coriell, GM05659) were transfected with Sendai virus for 4 days, and total RNAs were extracted using RNeasy Plus Mini Kit (Qiagen). The cDNA was reverse transcribed using 1 μg of RNA with the Superscript™ III First-Strand Synthesis SuperMix kit and amplification was performed using Platinum II Hot-Start PCR Master Mix (ThermoFisher) with the following program: 94 °C, 2 mins; 30 cycles of \[94 °C, 15 s, 60 °C, 15 s and 68 °C, 15 s\] on the Mastercycler pro S (Eppendorf) and primers are listed in [Table 2](#T2){ref-type="table"}. Products were loaded to the E-Gel® 1.2% with SYBR Safe™ gel, and imaged using the G: Box Chemi-XX6 gel doc system (Syngene).

Teratoma formation assay {#S13}
------------------------

The iPSCs were cultured in 6 well plates prior to dissociation with 0.5 mM EDTA in DPBS. Dissociated cells (1 × 10^7^) were resuspended in 400 μl culture medium supplemented with 25 mM HEPES (pH 7.4) and cooled on ice. Cold matrigel (Corning, 354277) was added and mixed with the cells at 50% volume (200 μl), then injected subcutaneously into NSG mice (JAX No. 005557) at 150 pi per injection site. Visible tumors were removed 6--18 weeks post injection, fixed in 10% Neutral Buffered Formalin, and then embedded in paraffin for staining with hematoxylin and eosin.

Supplementary Material {#SM1}
======================

We thank Dr. Zu-xi Yu of the Pathology Core of National Heart, Lung and Blood Institute, National Institutes of Health for sectioning and staining of the teratoma. We also would like to thank the Research Services Section at National Center for Advancing Translational Sciences for coordinating the STR DNA analysis and mycoplasma testing. This work was supported by the Intramural Research Program of the National Center for Advancing Translational Sciences, National Institutes of Health.

Supplementary data to this article can be found online at [http:\\\\doi.org/10.1016/j.scr.2019.101427](http:\\doi.org/10.1016/j.scr.2019.101427).

![Characterization of TRNDi006-A iPSC line A) Left panel shows phase contrast imaging of TRNDi006-A colonies grown on Matrigel at passage 10; Right panels show immunofluorescent staining of TRNDi006-A iPSCs, demonstrating expression of SOX2, OCT4, TRA-1-60, NANOG and SSEA4. Hoechst (blue) was used to label the nucleus. B) Pluripotency protein markers TRA-1-60, NANOG and SSEA4 were assessed by flow cytometry analysis. C) Normal karyotype was confirmed through G-banding karyotype analysis (46, XX). D) A homozygous gene mutation of p.Glu153Lys (c.457 G \> A) in the NAGLU gene was confirmed by Sanger sequencing. E) RT-PCR verification of the clearance of Sendai virus from the reprogrammed cells. Fibroblasts transfected with Sendai virus were used as positive control. F) Histological characterization of teratoma formation from TRNDi006-A, showing formation of three germ layers (Ectoderm, Mesoderm, and Endoderm).](nihms-1530901-f0001){#F1}

###### 

Characterization and validation.

  Classification                        Test                                   Result                                                                                                                                                Data
  ------------------------------------- -------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------
  Morphology                            Photography                            Normal                                                                                                                                                [Fig. 1](#F1){ref-type="fig"} Panel A
  Phenotype                             Immunocytochemistry                    SOX2, OCT4, NANOG, SSEA-4, TRA-1-60                                                                                                                   [Fig. 1](#F1){ref-type="fig"} Panel A
                                        Flow cytometry                         TRA-1-60 (99.98%); NANOG (96.08%); SSEA-4 (99.98%)                                                                                                    [Fig. 1](#F1){ref-type="fig"} Panel B
  Genotype                              Karyotype (G-banding) and resolution   46XX                                                                                                                                                  [Fig. 1](#F1){ref-type="fig"} Panel C
                                                                               Resolution: 350--400                                                                                                                                  
  Identity                              Microsatellite PCR (mPCR) OR           Not performed                                                                                                                                         N/A
                                        STR analysis                           18 sites tested, all sites matched                                                                                                                    Available with the authors
  Mutation analysis (if applicable)     Sequencing                             Homozygous mutation of NAGLU                                                                                                                          [Fig. 1](#F1){ref-type="fig"} Panel D
                                        Southern Blot OR WGS                   N/A                                                                                                                                                   N/A
  Microbiology and virology             Mycoplasma                             Mycoplasma testing by luminescence. Negative Teratoma with three germlayers formation. Ectoderm (neural tube); Mesoderm (cartilage); Endoderm (gut)   [Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}
  Differentiation potential             Teratoma formation                     [Fig. 1](#F1){ref-type="fig"} Panel F                                                                                                                 
  Donor screening (optional)            HIV 1 + 2 Hepatitis B, Hepatitis C     N/A                                                                                                                                                   N/A
  Genotype additional info (optional)   Blood group genotyping                 N/A                                                                                                                                                   N/A
  HLA tissue typing                     N/A                                    N/A                                                                                                                                                   

###### 

Reagents details

  Antibodies used for immunocytochemistry/flow-cytometry                                                       
  -------------------------------------------------------- ------------------------------------------ -------- ------------------------------------------------------------------------------------------------------
  Pluripotency Markers                                     Mouse anti-SOX2                            1:50     R & D systems, Cat\# MAB2018, RRID: [AB_358009](http://antibodyregistry.org/AB_358009)
  Pluripotency Markers                                     Rabbit anti-NANOG                          1:400    Cell Signaling, Cat\# 4903, RRID: [AB_10559205](http://antibodyregistry.org/AB_10559205)
  Pluripotency Markers                                     Rabbit anti-OCT4                           1:400    Thermo Fisher, Cat\# A13998, RRID: [AB_2534182](http://antibodyregistry.org/AB_2534182)
  Pluripotency Markers                                     Mouse anti-SSEA4                           1:1000   Cell Signaling, Cat\# 4755, RRID: [AB_1264259](http://antibodyregistry.org/AB_1264259)
  Pluripotency Markers                                     Mouse anti-TRA-1-60- Alexa Fluor 488       1:10     BD Biosciences, Cat\# 560173, RRID: [AB_1645379](http://antibodyregistry.org/AB_1645379)
  Secondary Antibodies                                     Donkey anti-Mouse IgG (Alexa Fluor 488)    1:400    Thermo Fischer, Cat\# A21202, RRID: [AB_141607](http://antibodyregistry.org/AB_141607)
  Secondary Antibodies                                     Donkey anti-Rabbit IgG (Alexa Fluor 594)   1:400    Thermo Fischer, Cat\# A21207, RRID: [AB_141637](http://antibodyregistry.org/AB_141637)
  Flow Cytometry Antibodies                                Anti-Tra-l-60-DyLight 488                  1:50     Thermo Fischer, Cat\# MA1-023-D488X, RRID: [AB_2536700](http://antibodyregistry.org/AB_2536700)
  Flow Cytometry Antibodies                                Anti-Nanog-Alexa Fluor 488                 1:50     Millipore, Cat\# FCABS352A4, RRID: [AB_10807973](http://antibodyregistry.org/AB_10807973)
  Flow Cytometry Antibodies                                anti-SSEA-4-Alexa Fluor 488                1:50     Thermo Fischer, Cat\# 53-8843-41, RRID: [AB_10597752](http://antibodyregistry.org/AB_10597752)
  Flow Cytometry Antibodies                                Mouse-IgM-DyLight 488                      1:50     Thermo Fischer, Cat\# MA1-194-D488, RRID: [AB_2536969](http://antibodyregistry.org/AB_2536969)
  Flow Cytometry Antibodies                                Rabbit IgG-Alexa Fluor 488                 1:50     Cell Signaling Technology, Cat\# 4340S, RRID: [AB_10694568](http://antibodyregistry.org/AB_10694568)
  Flow Cytometry Antibodies                                Mouse IgG3-FITC                            1:50     Thermo Fischer, Cat\# 11-4742-42, RRID: [AB_2043894](http://antibodyregistry.org/AB_2043894)
